Mountain peaks at sunrise
A welcoming home for HD research

Helping people make sense of Huntington's disease.

An open HD research hub for families, learners, and researchers. See what is changing, understand why it matters, and ask questions against the actual papers and trials.

Start here arrow_forward Ask a starter question chat
Latest HDBuzz + paper updates Trials 30 active, 23 recruiting Programs AMT-130, votoplam, SKY-0515

We are data scientists, not doctors. This is a research and education tool. For care decisions, please reach out to HDSA, HDBuzz, HDYO, or your own neurologist.

Start in 30 seconds

Pick the fastest path into the site, depending on what you need right now.

Need the latest
See what changed this week

Jump straight to the newest HD news, trial updates, and papers.
Need options
Browse active clinical trials

See what is recruiting now and which programs are moving.
Need clarity
Ask one good question

Start with a guided prompt instead of guessing what to search.
Who are you?

Tell us what kind of help you want.

Pick the lens that matches you. We will steer the chat, explainers, and suggested next steps to fit what you need.

Autonomous research agents
Cached records · 20 papers · 30 trials · 20 Open Targets associations
menu_book paper_scout
Paper scout cataloged 70 new papers (not analyzed; no LLM)
2 days ago
cloud_sync data_fetcher
Daily data refreshed
2 days ago
draft preprint_scout
Preprint scout indexed 84 HD preprints from biorxiv + medrxiv
3 days ago
science experiment_runner
Experiment #026 published
3 days ago
science experiment_runner
Experiment #025 published
3 days ago
science experiment_runner
Experiment #024 published
3 days ago
biotech hypothesis_refiner
Hypothesis refiner reviewed 80 drug ideas
Jul 15
What the agents pulled this week
Daily refresh · last attempts succeededEdge pipeline · catalog onlyExperiments shipped · 26Active hypotheses · 80
What we've learned

26 experiments. Methods, findings and limitations.

Every tracked effort is an experiment: a hypothesis, a method, a result, and a published log. The cards below are the latest complete version of each one. Older runs stay in the audit trail and are marked superseded.

EXP-001Mar 27, 2026

First-look LLM triage: 22 HD abstracts

The model analyzed 20 of 22 abstracts and surfaced recurring themes in huntingtin modifications, biomarkers and genetic mechanisms. These are exploratory literature signals, not clinical findings.

First run Mar 27, 2026 · llama3.1:8b View study arrow_forward
EXP-002Mar 30, 2026

Full-text analysis of 16 HD research papers

The synthesis highlighted LIG1 repair fidelity, genetic interventions and mitochondrial-inflammatory connections. Proposed links remain model-generated hypotheses rather than established treatment effects.

First run Mar 30, 2026 · llama3.1:8b View study arrow_forward
EXP-003-GEMMAApr 02, 2026

Gemma 4 analysis of the 16-paper corpus

Gemma proposed connections among protein aggregation, mitochondrial dysfunction, inflammation and metabolic regulation. This second Experiment 3 publication offers another model's interpretation, not a validated ranking against Llama.

First run Apr 02, 2026 · gemma4:latest View study arrow_forward
EXP-005Apr 19, 2026

Expanded corpus: genetic and metabolic hypotheses

The report proposes a two-track framing of genetic damage alongside metabolic and immune dysfunction, highlighting copper homeostasis and gut-brain research as topics for further investigation.

First run Apr 19, 2026 · gemma4:latest View study arrow_forward
EXP-006Jun 27, 2026

June 2026 literature update

The synthesis highlighted membrane lipid interactions, UCHL3-related proteostasis and DNA-repair or epigenetic pathways. These signals motivated subsequent focused literature experiments.

First run Jun 27, 2026 · gemma4:latest View study arrow_forward
EXP-007Jun 27, 2026

Lipid disruption and protein clearance in HD

The model favored a lipid-first hypothesis connecting membrane organization, mitochondrial stress and protein clearance. The proposed order is a research question, not demonstrated causality.

First run Jun 27, 2026 · gemma4:latest View study arrow_forward
EXP-008Jun 29, 2026

TET1 and epigenetic regulation in HD

The model proposed TET1 suppression as a contributing factor that may interact with lipid and proteostasis pathways. Candidate compounds in the report are hypotheses for research, not evidence of benefit or safety in people.

First run Jun 29, 2026 · gemma4:latest View study arrow_forward
EXP-009Jun 29, 2026

Gut-brain and neuronal excitability hypotheses

The report proposes links among gut barrier function, systemic metabolism and neuronal pathways. It draws on Parkinson's disease analogies, which do not establish that HD begins in the gut.

First run Jun 29, 2026 · gemma4:latest View study arrow_forward
EXP-010Jul 02, 2026

NAD+ metabolism and mitochondrial research

The model highlighted NAD+ metabolism as a research direction and proposed precursor, PARP and sirtuin-related hypotheses. The report does not demonstrate that any candidate improves outcomes in HD.

First run Jul 02, 2026 · gemma4:latest View study arrow_forward
EXP-011Jul 15, 2026

A footwear concept for chorea-related instability

The October 7 concept revision starts at an illustrative 115 mm width, with the archived 174 mm width available separately. Broad straps, pull loops, open fastening and heel/forefoot cells remain untested design choices. Neither width is a fit recommendation. The archived 83% is a model ratio, not a measured benefit. No tested shoe or suitable personal dimensions have been established.

First run Jul 15, 2026 · AI-assisted design study; model not recorded View study arrow_forward
EXP-003-V2Oct 04, 2026

Qwen comparison: the saved run timed out

All 16 paper analyses and the cross-paper synthesis failed with an Ollama read timeout at localhost:11434. The file records input size only. No Qwen finding was produced.

First run Apr 02, 2026 · qwen3.5:27b · this version Oct 04, 2026 · qwen3.5:27b (artifact audit; model not rerun) View study arrow_forward
EXP-004-V2Oct 04, 2026

Somatic CAG screen transcribed from the saved Gemma synthesis

The saved synthesis ranks MSH3, PMS1 and FAN1 and records 68 parsed analyses plus 7 JSON parse failures. Those ranks are the model's assessment, not a new measurement.

First run Apr 07, 2026 · gemma4:latest · this version Oct 04, 2026 · gemma4:latest (artifact audit; model not rerun) View study arrow_forward
EXP-024Oct 04, 2026

HDinHD access probe: no public catalog

Explorer redirects to a login page. The probe saved zero catalog rows. A normalizer and a synthetic fixture exist for when HDINHD_TOKEN is available.

First run Oct 04, 2026 · none (HTTP probe) View study arrow_forward
EXP-025Oct 04, 2026

Paper corpus catch-up after the May 5 stall

The scout corpus had stopped on 2026-05-05 at 86 papers while data_fetcher kept refreshing homepage papers. Discover-only search raised the corpus to 156 papers and analyzed none, because no LLM is configured.

First run Oct 04, 2026 · none (PubMed discovery) View study arrow_forward
EXP-012Oct 04, 2026

Kynurenine Pathway Dysregulation in HD — KMO, IDO1, and QUIN/KYNA Imbalance

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-013Oct 04, 2026

Complement Cascade & Neuroinflammation in HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-014Oct 04, 2026

Cognitive Pharmacotherapy in Huntington's Disease

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-015Oct 04, 2026

SEMA4D Neuroinflammation Axis in Huntington's Disease

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-016Oct 04, 2026

Mitochondrial Membrane Stabilization in HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-017Oct 04, 2026

PDE10A Inhibitors — Striatal cAMP/cGMP Rescue in HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-018Oct 04, 2026

GLP-1R Agonists — Neuroprotection Repurposing for HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-019Oct 04, 2026

MPC Inhibition & ISR Normalization in HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-020Oct 04, 2026

Ferroptosis & Iron Chelation in HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-021Oct 04, 2026

cGAS-STING Innate Immune Pathway in HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-022Oct 04, 2026

Adenosine A2A Receptor Antagonism for HD MSN Protection

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-023Oct 04, 2026

Thiamine + Biotin TCA Cycle Rescue in HD

The script was not run. No papers were fetched and no model output was produced. This page is the finished account of that block.

First run Oct 04, 2026 · not run View study arrow_forward
EXP-026Oct 04, 2026

What the shoe-building note actually connects to

The only HD shoe work found is Experiment #11, an unbuilt design study merged in PR 282. Named factories are capability examples, not partners. Other shoe hits in Ravi's repos are unrelated.

First run Oct 04, 2026 · none (repository search) View study arrow_forward

Superseded runs (kept for the audit trail, not featured)

  • EXP-003 Qwen model comparison: an incomplete run — superseded by EXP-003-V2.
  • EXP-004 Somatic CAG expansion literature screen — superseded by EXP-004-V2.
Browse experiments arrow_forward
How the Hub works

Pick a topic. Read what it means. Then do something with it.

Huntingtin-lowering (ASOs and gene therapy)

A strategy worth watching A simple idea, big stakes

Picture the huntingtin protein as a faulty thermostat that someone left turned up too high. Huntingtin-lowering programs try to turn the dial back down, so the brain has less of the harmful version to deal with in the first place.

What it is

A family of treatments that tries to make the brain produce less of the huntingtin protein. Some are repeat injections, some are a one-time gene therapy.

Read this at:
Do something with it
What the Hub is tracking today
20
Recent Papers
30
Active Trials
23
Recruiting Now
20
Open Targets associations (cached)

Snapshot recorded: October 04, 2026 at 05:35 PM (timezone not recorded). Refreshes scheduled daily; source results below.

PubMed: Refresh succeeded. Last successful refresh: October 04, 2026 at 05:35 PM (timezone not recorded). Last attempt: October 04, 2026 at 05:35 PM (timezone not recorded).

ClinicalTrials.gov: Refresh succeeded. Last successful refresh: October 04, 2026 at 05:35 PM (timezone not recorded). Last attempt: October 04, 2026 at 05:35 PM (timezone not recorded).

HDBuzz: Refresh succeeded. Last successful refresh: October 04, 2026 at 05:35 PM (timezone not recorded). Last attempt: October 04, 2026 at 05:35 PM (timezone not recorded).

Open Targets: Refresh succeeded. Last successful refresh: October 04, 2026 at 05:35 PM (timezone not recorded). Last attempt: October 04, 2026 at 05:35 PM (timezone not recorded).

What's Happening Now

HD News + Breakthroughs

More on HDBuzz open_in_new
30 Sep 2026

AMT-130 at Four Years: Hopeful Signs, Complex Controls
28 Sep 2026

September 2026: This month in Huntington’s disease research
24 Sep 2026

Studying Stutters: What 900,000 genomes teach us about growing DNA repeats
21 Sep 2026

Highlighting Mental Health Disparities in Indigenous Communities Affected by Huntington’s Disease
16 Sep 2026

Encouraging news from Skyhawk, as SKY-0515 Phase 1/2 data continues to hold promise
Fresh from PubMed

Latest Research Papers

All HD papers open_in_new
2026 Sep — Brain : a journal of neurology
somatic expansionprotein structure

The HTT1a protein initiates HTT aggregation in a knock-in mouse model of Huntington's disease.

The mutation that causes Huntington's disease is a CAG repeat expansion in exon 1 of the huntingtin gene (HTT) that leads to an abnormally long polyglutamine tract in the huntingtin protein (HTT). Mut

PubMed open_in_new
2026 Sep — Molecular biology reports
protein structure

Uncovering hidden protein networks in Huntington's disease: implications for pathogenesis and therap

Huntington's Disease is a neurodegenerative disorder that progresses over time and can be passed down from parent to child. In uncontrolled motor activities, behavioural problems come into play, as we

PubMed open_in_new
2026 Sep — Advanced science (Weinheim, Baden-Wurtte
drug repurposingautophagyprotein structure

Huntingtin Aggregate-Responsive Autophagy Gene Circuit Mitigates Disease Pathology in R6/2 Mice.

The accumulation of mutant huntingtin (mHTT) aggregates drives the pathology of Huntington's disease (HD), yet therapies capable of distinguishing toxic species from wild-type proteins remain elusive.

PubMed open_in_new
2026 Sep — Current neurology and neuroscience repor
biomarker

Fluid and Imaging Biomarkers in Huntington's Disease.

Growing interest in earlier and mechanism-targeted interventions for Huntington's disease (HD) has brought focus on biomarkers capable of informing trial design and regulatory pathways. This review di

PubMed open_in_new
2026 Oct — Philosophical transactions of the Royal
protein structure

Chaperone-mediated remodelling of mutant huntingtin.

Huntington's disease is caused by the trinucleotide repeat CAG expansion in the huntingtin gene, resulting in an N-terminal polyglutamine (polyQ) tract that renders the huntingtin protein (HTT) prone

PubMed open_in_new
2026 Sep — Journal of biomedical science
autophagyprotein structure

miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington's disease

Huntington's disease (HD) is a neurodegenerative disorder caused by abnormal expansions of poly-glutamine repeats in the mutant Huntingtin (mHTT). The expanded proteins form pathological aggregates to

PubMed open_in_new
Reasons for Optimism

Active Clinical Trials

30 tracked studies, 95 recorded as actual enrollment, 110,329 recorded as estimated enrollment, 23 recruiting now. These figures are the sum of the ClinicalTrials.gov enrollment fields in this table, not a count of unique patients.

ClinicalTrials.gov open_in_new
NCT ID Title Sponsor Phase Status Enrollment Enrollment type Intervention
NCT07609108 Pridopidine Phase 3 Study in Huntington's Disease Prilenia PHASE3 Recruiting 400 Estimated Pridopidine; Placebo
NCT05541627 A Study to Evaluate AB-1001 Striatal Administratio AskBio France, SAS, a sub PHASE1, PHASE2 Active Not Recruiting 5 Actual AB-1001 Gene Therapy
NCT06626412 Longitudinal SV2A PET and MRI in Premanifest HD Universitaire Ziekenhuize NA Active Not Recruiting 40 Estimated Diagnostic Test: 18F-SynVesT-1 PET; Volu
NCT07378644 Study to Evaluate the Pharmacodynamics, Safety and Skyhawk Therapeutics, Inc PHASE2, PHASE3 Recruiting 400 Estimated SKY-0515; SKY-0515 Placebo
NCT06312189 Long-term Study to Evaluate Safety and Tolerabilit Neurocrine Biosciences PHASE3 Enrolling By Invitation 7 Estimated Valbenazine
NCT06626308 Early Biomarkers in Premanifest Huntington's Disea University Hospital, Gren NA Recruiting 20 Estimated brain functional MRI
NCT06843252 Home-based TDCS (Transcranial Direct Current Stimu The University of Texas H NA Recruiting 16 Estimated Transcranial direct current stimulation
NCT07503743 Biology-Driven Cognitive Profiling in Huntington's Fundació Institut de Rece N/A Active Not Recruiting 90 Actual
NCT06828471 Social Cognition Training in Individuals With Hunt Rush University Medical C NA Recruiting 20 Estimated Social Cognition Training
NCT01574053 Enroll -HD: A Prospective Registry Study in a Glob CHDI Foundation, Inc. N/A Recruiting 35,000 Estimated
NCT07253038 Evaluation of Three Tests to Assess Social Cogniti Region Skane N/A Recruiting 40 Estimated
NCT02994719 Gait Analysis in Neurological Disease Beth Israel Deaconess Med N/A Active Not Recruiting 120 Estimated Anti-Parkinson medication; Deep Brain St
NCT00874783 Development of IPS from Donated Somatic Cells of P Hadassah Medical Organiza N/A Recruiting 120 Estimated
NCT06873334 Study of SKY-0515 for Safety, Efficacy, and Pharma Skyhawk Therapeutics, Inc PHASE2, PHASE3 Active Not Recruiting 120 Estimated SKY-0515; SKY-0515 Placebo
NCT06147414 Development of Non-Invasive Prenatal Diagnosis for Assistance Publique - Hôp N/A Recruiting 550 Estimated Blood sample
NCT06203106 NYSCF Scientific Discovery Biobank New York Stem Cell Founda N/A Recruiting 10,000 Estimated Biological Sample Collection
NCT07536061 A First-in-human Study of the Effects of SRP-1005 Sarepta Therapeutics, Inc PHASE1 Recruiting 32 Estimated SRP-1005; Placebo
NCT07451613 Safety and Tolerability Study of Human Neural Stem Leslie Thompson PHASE1, PHASE2 Recruiting 21 Estimated hNSC-01
NCT07010705 Digital Measures for Clinical Trial Endpoints in H University of Rochester N/A Recruiting 100 Estimated ActiGraph LEAP; Axivity AX6
NCT06209515 Sociodemographic Factors and Criminal Behaviour Pr Kuopio University Hospita N/A Active Not Recruiting 61,292 Estimated
NCT06774443 Hinting Task for Huntington's Disease University Medical Center N/A Recruiting 52 Estimated Neuropsychological assessment
NCT04012411 Study of BDNF Pathway Biomarkers in the Cerebrospi University Hospital, Mont NA Recruiting 135 Estimated Brain MRI; Lumbar Punction; Blood sample
NCT05822908 A Safety and Pharmacokinetics Trial of VO659 in SC Vico Therapeutics B. V. PHASE1, PHASE2 Recruiting 68 Estimated VO659
NCT06782230 ScATtEred Rare Disease Biobanks: a Model of Sample IRCCS Policlinico S. Dona N/A Recruiting 800 Estimated
NCT06634628 iMagemHTT-009- FIH Evaluation of Novel Mutant Hunt CHDI Foundation, Inc. EARLY_PHASE1 Recruiting 27 Estimated Radioligand [11C]CHDI-00491009
NCT06448546 Gut Microbiomes in HD University of Central Flo N/A Recruiting 36 Estimated
NCT06826612 A Randomized Study of SPK-10001 Gene Therapy in Pa Hoffmann-La Roche PHASE1, PHASE2 Recruiting 53 Estimated SPK-10001; Placebo Surgery Control
NCT07326709 A Study to Investigate the Efficacy, Safety and To Novartis Pharmaceuticals PHASE3 Recruiting 770 Estimated Votoplam (blinded); Placebo
NCT06585449 A Study to Evaluate ALN-HTT02 in Adult Patients Wi Alnylam Pharmaceuticals PHASE1 Recruiting 66 Estimated ALN-HTT02; Placebo
NCT07513844 Optimizing Parameters of Low-Intensity Focused Ult First Affiliated Hospital NA Recruiting 24 Estimated Low-Intensity Focused Ultrasound Stimula
Open Research

Published Research Ideas

AI-assisted repurposing ideas with explicit uncertainty. These are starting points for review, not recommendations or validated findings.

Read Experiment #1: Full Analysis arrow_forward
TET1 activators / DNMT inhibitors (ascorbate, decitabine) Exploring
Target: TET1 / DNA methylation / epigenetic gene silencing

New June 2026 knock-in pig study (PMID 42322611): mHTT disrupts TBP binding to the TET1 promoter, silencing TET1 transcription before symptom onset. TET1 converts 5mC to 5hmC (DNA demethylation); its loss causes aberrant

Latest score: 90/100 Support: 5 Concerns: 3 Updated: 2026-06-29
anle138b Exploring
Target: mHTT oligomers / lipid raft disruption

Oligomer inhibitor shown to ameliorate HD pathology in mouse and cellular models. Exp 6 signal: mHTT hijacks neuronal lipid rafts; anle138b stabilizes oligomer conformation before raft association. Preclinical confidence

Latest score: 90/100 Support: 2 Concerns: 0 Updated: 2026-06-27
CYP46A1 activators (efavirenz) Exploring
Target: CYP46A1 / cholesterol catabolism / lipid raft stabilization

Exp 7 identified CYP46A1 activation as the highest-confidence early intervention: restoring cholesterol catabolism may stabilize lipid raft microdomains disrupted by mHTT, preventing the downstream proteostasis cascade.

Latest score: 88/100 Support: 3 Concerns: 1 Updated: 2026-06-27
HTT1a-selective ASO/RNA therapy Exploring
Target: HTT1a transcript isoform / selective mHTT lowering

New June 2026 paper: selectively targeting HTT1a isoform provides superior molecular rescue vs. lowering canonical HTT. HTT1a is enriched in disease-vulnerable neurons. Isoform-selective lowering preserves full-length HT

Latest score: 85/100 Support: 3 Concerns: 2 Updated: 2026-06-27
PROTACs (Proteolysis Targeting Chimeras) for selective mHTT degradation Preclinical
Target: Mutant HTT protein / proteasome-ubiquitin system / selective protein degradation

HDBuzz Jun 25 2026: PROTACs act as molecular glue, recruiting E3 ubiquitin ligases to tag mutant huntingtin (mHTT) for proteasomal destruction while leaving wild-type HTT intact. Unlike ASOs/siRNA (which lower all HTT mR

Latest score: 83/100 Support: 5 Concerns: 4 Updated: 2026-06-29
Somatic CRISPR editing of Msh3 Exploring
Target: Msh3 / somatic CAG expansion / DNA mismatch repair

New June 2026 paper: somatic CRISPR knockout of Msh3 mitigates HD pathology in mice. Msh3 drives somatic CAG repeat expansion in neurons — without it, the repeat stays stable. This is a one-time intervention that targets

Latest score: 82/100 Support: 3 Concerns: 2 Updated: 2026-06-27

Important: These hypotheses are triage artifacts, not evidence of efficacy. They have not been clinically validated, experimentally confirmed, or expert-reviewed unless explicitly stated.

These cards are generated from data/hypotheses_tracker.json, not hand-picked homepage copy. Are you an HD researcher? We'd love your feedback. Review and discuss on GitHub

waving_hand

Who This Is For

This is best viewed as open research infrastructure: a place where data scientists, AI engineers, bioinformaticians, and researchers can test whether agent workflows actually help with literature review, hypothesis triage, and research communication.

Data Scientists + AI/ML Engineers

Run our autonomous research agents. Fork the repo. Try different models. Add experiments. This is open-source infrastructure you can build on.

Researchers + Domain Experts

Review our AI-generated hypotheses. Spot what's promising and what's wrong. Your expertise is what turns computational ideas into real science. Join the discussion.

Students + Curious Builders

Want to learn how AI applies to drug discovery? Read our experiment reports — we show every step, what worked, and what didn't. No PhD required to follow along.

For patients and families: This is not a medical resource. For support, guidance, and verified medical information, please go to HDSA, HDBuzz, or HDYO. They have doctors and scientists reviewing every word. We don't.

Trusted Organizations

Resources for Patients, Families + Researchers

These organizations are the real experts. We link to them because they do essential work.

HDSA
Support + Advocacy

Huntington's Disease Society of America. Find local support groups, social workers, Centers of Excellence. The primary advocacy organization in the US.
HDBuzz
Research News in Plain Language

Scientists explain HD research in words everyone can understand. The best place to follow new developments without needing a PhD.
HDYO
Young People

Huntington's Disease Youth Organization. Resources specifically for young people affected by HD — teens, young adults, and young families.
Enroll-HD
Join Research

The world's largest observational study for HD families. Your data helps researchers understand HD and design better clinical trials.
European HD Network
International Research

EHDN coordinates HD research across Europe. Clinical trials, registries, and working groups advancing the science globally.
HD Reach
Rehab + Exercise

Evidence-based rehabilitation exercises designed for people with HD. Physical therapy, speech therapy, and occupational therapy resources.
Make a Difference

Ways to Get Involved

Whether you're a patient, family member, researcher, developer, or just someone who cares.

volunteer_activism

Join a Clinical Trial

23 HD trials are actively recruiting right now. Your participation directly accelerates the path to treatment.

Find recruiting trials open_in_new
code

Contribute to Open Source

Our research agent, literature scanner, and drug repurposing tools are all open source. Data scientists, ML engineers, and bioinformaticians welcome.

View on GitHub open_in_new
record_voice_over

Share Your Story

Patient and family stories drive awareness and funding. Share your experience with HDSA or on social media to help others feel less alone.

HDSA Get Involved open_in_new
favorite

Donate

Research funding saves lives. HDSA and CHDI Foundation fund the science that makes breakthroughs like AMT-130 possible.

Donate to HDSA open_in_new
forum

Share Feedback or Ideas

Are you an HD researcher? See something interesting in our hypotheses? Spot an error? We want to hear from you — every correction makes this better.

Join the Discussion open_in_new